0001310630 false --12-31 Q2 0001310630 2022-01-01 2022-06-30 0001310630 2022-08-15 0001310630 2022-06-30 0001310630 2021-12-31 0001310630 2022-04-01 2022-06-30 0001310630 2021-04-01 2021-06-30 0001310630 2021-01-01 2021-06-30 0001310630 us-gaap:CommonStockMember 2021-12-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001310630 us-gaap:RetainedEarningsMember 2021-12-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001310630 us-gaap:CommonStockMember 2022-03-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001310630 us-gaap:RetainedEarningsMember 2022-03-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001310630 2022-03-31 0001310630 us-gaap:CommonStockMember 2020-12-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001310630 us-gaap:RetainedEarningsMember 2020-12-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001310630 2020-12-31 0001310630 us-gaap:CommonStockMember 2021-03-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001310630 us-gaap:RetainedEarningsMember 2021-03-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001310630 2021-03-31 0001310630 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001310630 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001310630 2022-01-01 2022-03-31 0001310630 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001310630 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001310630 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001310630 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001310630 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001310630 2021-01-01 2021-03-31 0001310630 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001310630 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001310630 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001310630 us-gaap:CommonStockMember 2022-06-30 0001310630 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001310630 us-gaap:RetainedEarningsMember 2022-06-30 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001310630 us-gaap:CommonStockMember 2021-06-30 0001310630 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001310630 us-gaap:RetainedEarningsMember 2021-06-30 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001310630 2021-06-30 0001310630 CFOO:EliteCreationGroupLimitedMember 2022-01-01 2022-06-30 0001310630 CFOO:AlphaWellnessHKLimitedMember 2022-01-01 2022-06-30 0001310630 CFOO:GuangzhouXiaoXiangHealthIndustryCompanyLimitedMember 2022-01-01 2022-06-30 0001310630 CFOO:FurnitureFixtureAndEquipmentMember 2022-01-01 2022-06-30 0001310630 CFOO:FurnitureFixtureAndEquipmentMember 2022-06-30 0001310630 CFOO:MotorVehiclesMember srt:MinimumMember 2022-01-01 2022-06-30 0001310630 CFOO:MotorVehiclesMember srt:MaximumMember 2022-01-01 2022-06-30 0001310630 CFOO:MotorVehiclesMember 2022-06-30 0001310630 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-06-30 0001310630 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001310630 CFOO:ConsultancyServiceFeeIncomeMember 2022-04-01 2022-06-30 0001310630 CFOO:ConsultancyServiceFeeIncomeMember 2021-04-01 2021-06-30 0001310630 CFOO:SalesofHealthcareMember 2022-04-01 2022-06-30 0001310630 CFOO:SalesofHealthcareMember 2021-04-01 2021-06-30 0001310630 CFOO:ConsultancyServiceFeeIncomeMember 2022-01-01 2022-06-30 0001310630 CFOO:ConsultancyServiceFeeIncomeMember 2021-01-01 2021-06-30 0001310630 CFOO:SalesofHealthcareMember 2022-01-01 2022-06-30 0001310630 CFOO:SalesofHealthcareMember 2021-01-01 2021-06-30 0001310630 CFOO:PeriodEndHKUSExchangeRateMember 2022-06-30 0001310630 CFOO:PeriodEndHKUSExchangeRateMember 2021-06-30 0001310630 CFOO:PeriodAverageHKUSExchangeRateMember 2022-06-30 0001310630 CFOO:PeriodAverageHKUSExchangeRateMember 2021-06-30 0001310630 CFOO:PeriodEndRMBUSExchangeRateMember 2022-06-30 0001310630 CFOO:PeriodEndRMBUSExchangeRateMember 2021-06-30 0001310630 CFOO:PreiodAverageRMBUSExchangeRateMember 2022-06-30 0001310630 CFOO:PreiodAverageRMBUSExchangeRateMember 2021-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:ConsultancyServiceFeeIncomeMember 2022-04-01 2022-06-30 0001310630 CFOO:WineSegmentMember CFOO:ConsultancyServiceFeeIncomeMember 2022-04-01 2022-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SalesofHealthcareProductsMember 2022-04-01 2022-06-30 0001310630 CFOO:WineSegmentMember CFOO:SalesofHealthcareProductsMember 2022-04-01 2022-06-30 0001310630 CFOO:SalesofHealthcareProductsMember 2022-04-01 2022-06-30 0001310630 CFOO:HealthcareSegmentMember 2022-04-01 2022-06-30 0001310630 CFOO:WineSegmentMember 2022-04-01 2022-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SalesofHealthcareMember 2022-04-01 2022-06-30 0001310630 CFOO:WineSegmentMember CFOO:SalesofHealthcareMember 2022-04-01 2022-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:ConsultancyServiceFeeIncomeMember 2021-04-01 2021-06-30 0001310630 CFOO:WineSegmentMember CFOO:ConsultancyServiceFeeIncomeMember 2021-04-01 2021-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SalesofHealthcareMember 2021-04-01 2021-06-30 0001310630 CFOO:WineSegmentMember CFOO:SalesofHealthcareMember 2021-04-01 2021-06-30 0001310630 CFOO:HealthcareSegmentMember 2021-04-01 2021-06-30 0001310630 CFOO:WineSegmentMember 2021-04-01 2021-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:ConsultancyServiceFeeIncomeMember 2022-01-01 2022-06-30 0001310630 CFOO:WineSegmentMember CFOO:ConsultancyServiceFeeIncomeMember 2022-01-01 2022-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SalesofHealthcareMember 2022-01-01 2022-06-30 0001310630 CFOO:WineSegmentMember CFOO:SalesofHealthcareMember 2022-01-01 2022-06-30 0001310630 CFOO:HealthcareSegmentMember 2022-01-01 2022-06-30 0001310630 CFOO:WineSegmentMember 2022-01-01 2022-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:ConsultancyServiceFeeIncomeMember 2021-01-01 2021-06-30 0001310630 CFOO:WineSegmentMember CFOO:ConsultancyServiceFeeIncomeMember 2021-01-01 2021-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SalesofHealthcareMember 2021-01-01 2021-06-30 0001310630 CFOO:WineSegmentMember CFOO:SalesofHealthcareMember 2021-01-01 2021-06-30 0001310630 CFOO:HealthcareSegmentMember 2021-01-01 2021-06-30 0001310630 CFOO:WineSegmentMember 2021-01-01 2021-06-30 0001310630 srt:MinimumMember 2022-06-30 0001310630 srt:MaximumMember 2022-06-30 0001310630 CFOO:MotorVehicleMember 2022-06-30 0001310630 CFOO:MotorVehicleMember 2021-12-31 0001310630 CFOO:FurnitureFixtureAndEquipmentMember 2021-12-31 0001310630 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001310630 CFOO:ForeignTranslationDifferenceMember 2022-06-30 0001310630 CFOO:ForeignTranslationDifferenceMember 2021-12-31 0001310630 country:CN 2022-01-01 2022-06-30 0001310630 country:HK 2022-01-01 2022-06-30 0001310630 country:CN 2021-01-01 2021-06-30 0001310630 country:HK 2021-01-01 2021-06-30 0001310630 country:US 2022-06-30 0001310630 country:US 2021-12-31 0001310630 country:CN 2022-06-30 0001310630 country:CN 2021-12-31 0001310630 CFOO:CustomerCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001310630 CFOO:CustomerDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001310630 CFOO:CustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001310630 CFOO:CustomerCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001310630 CFOO:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-06-30 0001310630 CFOO:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001310630 CFOO:CustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001310630 CFOO:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-06-30 0001310630 CFOO:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001310630 CFOO:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001310630 CFOO:CustomerBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001310630 CFOO:CustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001310630 CFOO:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001310630 CFOO:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-06-30 0001310630 CFOO:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001310630 CFOO:CustomerBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001310630 CFOO:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-06-30 0001310630 CFOO:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001310630 CFOO:CustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001310630 CFOO:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-06-30 0001310630 CFOO:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001310630 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember CFOO:VendorMember 2022-04-01 2022-06-30 0001310630 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember CFOO:VendorMember 2022-01-01 2022-06-30 0001310630 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember CFOO:VendorMember 2022-04-01 2022-06-30 0001310630 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember CFOO:VendorMember 2022-06-30 0001310630 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember CFOO:VendorMember 2022-01-01 2022-06-30 0001310630 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember CFOO:VendorMember 2021-04-01 2021-06-30 0001310630 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember CFOO:VendorMember 2021-01-01 2021-06-30 0001310630 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember CFOO:VendorMember 2021-04-01 2021-06-30 0001310630 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember CFOO:VendorMember 2021-06-30 0001310630 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember CFOO:VendorMember 2021-01-01 2021-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:HKD CFOO:Integer iso4217:CNY

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2022 or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________to _________

 

001-32522

Commission file number

 

China Foods Holdings Ltd.

(Exact name of registrant as specified in its charter)

 

Delaware   84-1735478

State or other jurisdiction

of incorporation or organization

 

(I.R.S. Employer

Identification No.)

 

Room 2301A, China Resources Building,

26 Harbour Road,

Wanchai, Hong Kong

 

0000

(Address of principal executive offices)   (Zip Code)

 

(852) 3618-8608

 

Registrant’s telephone number, including area code

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically on its corporate Web site, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date.

 

Class   Outstanding August 15, 2022
Common Stock, with $0.0001 par value   20,252,309 shares

 

 

 

 

 

 

Table of Contents

 

    Page
    No.
  PART I – FINANCIAL INFORMATION  
     
Item 1.

Condensed Consolidated Financial Statements (Unaudited)

3
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 24
     
Item 4. Controls and Procedures 24
     
  PART II – OTHER INFORMATION  
     
Item 1. Legal Proceedings 24
     
Item 1A. Risk Factors 24
     
Item 2. Unregistered Sales of Equity Securities and Proceeds 24
     
Item 3. Defaults Upon Senior Securities 24
     
Item 4. Mine Safety Disclosure 24
     
Item 5. Other Information 24
     
Item 6. Exhibits 25
     
SIGNATURES 26

 

2

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

China Foods Holdings Ltd.

Condensed Consolidated Balance Sheets

 

  

June 30,

2022

  

December 31,

2021

 
   $   $ 
   (Unaudited)   (Audited) 
ASSETS          
           
Current Assets          
Cash and cash equivalents   477,214    609,434 
Prepayments and other receivables   123,956    139,254 
Inventories   300,521    327,551 
Tax recoverable   70    8,910 
Right-of-use assets   278,235    350,563 
Total Current Assets   1,179,996    1,435,712 
           
Non-Current Assets          
Plant and equipment   92,866    132,604 
Intangible assets   3,493    3,947 
Total Non-Current Assets   96,359    136,551 
           
TOTAL ASSETS   1,276,355    1,572,263 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
           
Current Liabilities          
Accrued liabilities and other payables   58,339    51,200 
Customer deposits   246,951    340,783 
Lease liabilities   106,888    114,132 
Amount due to a director   214,665    219,461 
Amount due to a related company   199,964    199,964 
Total Current Liabilities   826,807    925,540 
           
Non-Current Liabilities          
Lease liabilities   183,050    246,022 
Total Non-Current Liabilities   183,050    246,022 
           
Stockholders’ Equity          
Common stock $0.0001 par value, 100,000,000 shares authorized, 20,252,309 and 20,252,309 shares issued and outstanding as of June 30, 2022 and December 31, 2021 respectively   2,025    2,025 
Additional paid-in capital   1,290,355    1,290,355 
Accumulated other comprehensive income   6,860    26,516 
Accumulated deficit   (1,032,742)   (918,195)
Total Shareholders’ Equity   266,498    400,701 
           
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY   1,276,355    1,572,263 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

3

 

 

China Foods Holdings Ltd.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

 

   Three Months Ended   Three Months Ended   Six Months Ended   Six Months Ended 
   June 30, 2022   June 30, 2021   June 30, 2022   June 30, 2021 
                 
Revenue, net   94,835    266,926    163,634    434,569 
                     
Cost of revenue   (28,474)   (59,284)   (47,311)   (212,968)
                     
Gross profit   66,361    207,642    116,323    221,601 
                     
Operating expenses                    
Selling and distribution expenses   2,642    2,563    2,650    14,212 
General and administrative expenses   107,762    170,800    232,691    384,976 
Total operating expenses   110,404    173,363    235,341    399,188 
                     
(Loss) income from operation   (44,043)   34,279    (119,018)   (177,587)
                     
Other Income                    
Interest income   36    361    113    871 
Sundry income   10,589    30    10,931    6,319 
Total other income   10,625    391    11,044    7,190 
                     
(Loss) income before income tax   (33,418)   34,670    (107,974)   (170,397)
                     
Income tax expenses   (4,305)   -    (6,573)   - 
                     
Net (loss) income   (37,723)   34,670    (114,547)   (170,397)
                     
Other comprehensive (loss) income                    
Foreign currency adjustment gain (loss)   (19,054)   12,037    (19,656)   13,893 
                     
Comprehensive (loss) income   (56,777)   46,707    (134,203)   (156,504)
                     
Net (loss) income per common share                    
Basic and diluted*  $(0.00)   $0.00   $(0.01)  $(0.01)
                     
Weighted average number of common share                    
 Basic and diluted   20,252,309    20,252,309    20,252,309    20,252,309 

 

*denotes net loss per common share of less than $0.01 per share.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

4

 

 

CHINA FOODS HOLDINGS LTD.

Condensed Consolidated Statements of Changes in Shareholders’ Equity

(Unaudited)

 

   Share   Amount   capital   Deficit   income   Equity 
   Common Stock  

Additional

paid-in

  

Accumulated

  

Accumulated

other

comprehensive

  

Total

shareholders’

 
   Share   Amount   capital   Deficit   income   Equity 
         $    $    $    $    $ 
                               
Balance at January 1, 2022   20,252,309    2,025    1,290,355    (918,195)   26,516    400,701 
                               
Net loss for the period   -    -    -    (76,824)   -    (76,824)
                               
Foreign currency translation adjustment   -    -    -    -    (602)   (602)
                               
Balance at March 31, 2022   20,252,309    2,025    1,290,355    (995,019)   25,914    323,275 
                               
Net loss for the period   -    -    -    (37,723)   -    (37,723)
                               
Foreign currency translation adjustment   -    -    -    -    (19,054)   (19,054)
                               
Balance at June 30, 2022   20,252,309    2,025    1,290,355    (1,032,742)   6,860    266,498 

 

   Common Stock  

Additional

paid-in

   Accumulated  

Accumulated

other

comprehensive

  

Total

shareholders’

 
   Share   Amount   capital   Deficit   income   Equity 
         $    $    $    $    $ 
                               
Balance at January 1, 2021   20,252,309    2,025    1,290,355    (462,786)   5,244    834,838 
                               
Net loss for the period   -    -    -    (205,067)   -    (205,067)
                               
Foreign currency translation adjustment   -    -    -    -    1,856    1,856 
                               
Balance at March 31, 2021   20,252,309    2,025    1,290,355    (667,853)   7,100    631,627 
                               
Net income for the period   -    -    -    34,670    -    34,670 
                               
Foreign currency translation adjustment   -    -    -    -    12,037    12,037 
                               
Balance at June 30, 2021   20,252,309    2,025    1,290,355    (633,183)   19,137    678,334 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

5

 

 

China Foods Holdings Ltd.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   June 30, 2022   June 30, 2021 
   Six months ended 
   June 30, 2022   June 30, 2021 
Cash flows from operating activities:          
Net loss  $(114,547)  $(170,397)
Adjustments to reconcile net loss to net cash used in operating activities          
Depreciation   36,191    42,671 
Amortization   259    260 
Non-cash lease expense   35,814    7,485 
    (42,283)   (119,981)
Change in operating assets and liabilities:          
Accounts receivables   -    (167,223)
Prepayments and other receivables   15,298    (9,185)
Inventories   27,030    65,411 
Accrued liabilities and other payables   7,139    46,084 
Accounts payable   -    (7,827)
Tax payable   8,840    7,305 
Customer deposits   (93,832)   (128,499)
Lease liabilities   (49,104)   36,135 
Net cash used in operating activities   (126,912)   (277,780)
           
Cash flows from financing activities:          
Repayment of lease liabilities   -    (31,721)
(Repayment to) advances from a director   (4,796)   81,899 
Net cash (used in) provided by financing activities   (4,796)   50,178 
           
Foreign currency translation adjustment   (512)   4,979 
           
Net change in cash and cash equivalents   (132,220)   (222,623)
           
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD   609,434    1,006,394 
           
CASH AND CASH EQUIVALENTS, END OF PERIOD  $477,214   $783,771 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION          
Cash paid for interest  $-   $- 
Cash paid for income taxes  $-   $- 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

6

 

 

China Foods Holdings Ltd.

Notes to the Unaudited Condensed Consolidated Financial Statements

Six months ended June 30, 2022

 

NOTE 1 – NATURE OF OPERATIONS

 

China Foods Holdings Ltd. (the “Company”) was incorporated in Delaware on January 10, 2019. On July 9, 2020, the Company consummated the Share Exchange Agreement (“the “Share Exchange Agreement”) with Elite Creation Group Limited, a private limited company organized under the laws of British Virgin Islands (“ECGL”). As a result of the acquisition of ECGL, the Company entered into the healthcare product distributing and marketing industry, pursuing a new strategy of developing and distributing health related products, including supplements, across the globe with a focus on mainland China, Europe and Australia.

 

We are a health and wellness company that develops, markets, promotes and distributes a variety of customized health and wellness care products and services, including supplements, healthy snacks, meal replacements, skincare products, and nutritional consultation services to consumers in China. We work with certain licensed healthcare food factories to develop and manufacture products and services that are distributed conventionally through sales agents and also through a network of e-commerce and social media platforms.

 

In addition to products, we are committed to providing customized science based wellness consultation and service programs to customers. Our diverse products and services target health conscious customers and differentiate based upon age and gender and seek to manage different conditions. We reach out to customers fitting certain health and lifestyle profiles through our offline and online consultation services, and track eating habits and health indicators to provide customized products such as supplements. We believe this will facilitate the ability of customers to monitor, understand and adjust their health practices and lifestyle anytime and anywhere for increased customer engagement and retention.

 

We conduct our business through our wholly owned subsidiary Guangzhou Xiao Xiang Health Industry Company Limited, a limited liability company organized under the laws of China on March 8, 2017 and Alpha Wellness (HK) Limited, a limited liability company organized under the laws of Hong Kong on April 24, 2019. Elite Creation Group, a limited liability company formed under the laws of the British Virgin Islands formed on September 5, 2018, is holding companies without operations.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation and consolidation

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting, and in accordance with instructions for Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the unaudited condensed consolidated financial statements contained in this report reflect all adjustments that are normal and recurring in nature and considered necessary for a fair presentation of the financial position and the results of operations for the interim periods presented. The year-end balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. The results of operations for the interim period are not necessarily indicative of the results expected for the full year. These unaudited condensed consolidated financial statements, footnote disclosures and other information should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

 

The unaudited condensed consolidated financial statements are presented in US Dollars and include the accounts of the Company and its subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation.

 

7

 

 

The following table depicts the description of the Company’s subsidiaries:

 

Name  Place of incorporation
and kind of
legal entity
  Principal
activities
  Particulars of
registered/
paid up share
capital
  Effective interest
held
 
              
Elite Creation Group Limited  BVI, a limited liability company  Investment holding  50,000 issued shares of US$1 each   100%
               
Alpha Wellness (HK) Limited  Hong Kong, a limited liability company  Investment holding  300,000 issued shares for HK$300,000   100%
               
Guangzhou Xiao Xiang Health Industry Company Limited  The PRC, a limited liability company  Sales of healthcare products  RMB 8,300,000   100%

 

Cash and cash equivalents

 

Cash and cash equivalents are carried at cost and represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.

 

Inventories

 

Inventories are stated at the lower of cost or market value (net realizable value), cost being determined on a first-in-first-out method. Costs include material and manufacturing overhead costs. The Company provides inventory allowances based on excess and obsolete inventories determined principally by customer demand. As of June 30, 2022 and December 31, 2021, the Company did not record an allowance for obsolete inventories, nor have there been any write-offs.

 

Plant and equipment

 

Plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on the straight-line basis over the following expected useful lives from the date on which they become fully operational and after taking into account their estimated residual values:

 

   Expected useful lives  Residual value 
Furniture, fixture and equipment  3 years   5%
Motor vehicle  3.33 to 4 years   5%
Leasehold improvement  2 years   5%

 

Expenditures for repairs and maintenance are expensed as incurred. When assets have been retired or sold, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in the results of operations.

 

Depreciation expense for the three and six months ended June 30, 2022 were $16,573 and $36,191, respectively, and for the three and six months ended June 30, 2021 were $21,241 and $42,671, respectively.

 

Intangible assets

 

Intangible assets represented trademarks of their products and are stated at cost less accumulated amortization and any recognized impairment loss. Amortization is provided over the term of their registrations on a straight-line basis, which is 10 years and will expire in 2028.

 

Amortization expense for the three and six months ended June 30, 2022 were $127 and $259, respectively.

 

Amortization expense for the three and six months ended June 30, 2021 were $130 and $260, respectively.

 

Impairment of long-lived assets

 

In accordance with the provisions of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, all long-lived assets such as plant and equipment, as well as intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets. There has been no impairment charge for the periods presented.

 

8

 

 

Revenue recognition

 

The Company adopted Accounting Standards Codification (“ASC”) Topic 606 – Revenue from Contracts with Customers” (“ASC Topic 606”). Under ASC Topic 606, a performance obligation is a promise within a contract to transfer a distinct good or service, or a series of distinct goods and services, to a customer. Revenue is recognized when performance obligations are satisfied and the customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for goods or services. Under the standard, a contract’s transaction price is allocated to each distinct performance obligation. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps:

 

  identify the contract with a customer;
  identify the performance obligations in the contract;
  determine the transaction price;
  allocate the transaction price to performance obligations in the contract; and
  recognize revenue as the performance obligation is satisfied.

 

Currently, the Company operates two business segments, the Healthcare Business and the Wine Business.

 

The Healthcare Business mainly provides health consulting advisory services and healthcare and wellness products to the customers.

 

Revenue is earned from the rendering of health consulting advisory services to the customers. The Company recognizes services revenue over the period in which such services are performed. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

 

The sale and distribution of the healthcare products, such as (i) Nutrition Catering (ii) Special Health Food (iii) Health Supplement and (iv) Skincare, is the only performance obligation under the fixed-fee arrangements. Revenue is recognized from the sale of their healthcare products upon delivery to the customers, whereas the title and risk of loss are fully transferred to the customers. The Company records its revenues, net of value added taxes (“VAT”) on the majority of the products at the rate of 17% on the invoiced value of sales. The cost, such as shipping cost and material cost, is recognized when the product delivered to the customers. The Company records its cost including taxes.

 

The Wine Business mainly provides the wine products to the customers. Revenue is recognized from the sale of wine products upon delivery to the customers, whereas the title and risk of loss are fully transferred to the customers. The Company records its revenues, net of value added taxes (“VAT”) on the majority of the products at the rate of 17% on the invoiced value of sales. The Company recorded no product sales returns for the six months ended June 30, 2022 and 2021. The cost, such as shipping cost and material cost, is recognized when the product delivered to the customers. The Company records its cost including taxes.

 

Disaggregation of Revenue

 

The following table provides information about disaggregated revenue from customers into the nature of the products and services, and geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments.

 

           
   For the Three Months Ended June 30, 2022   For the Three Months Ended June 30, 2021 
         
Consultancy service income  $71,394   $165,640 
Sales of healthcare   23,441    101,286 
           
TOTAL  $94,835   $266,926 

 

           
  

For the Six Months Ended June 30, 2022

  

For the Six Months Ended June 30, 2021

 
         
Consultancy service income  $135,452   $165,640 
Sales of healthcare   28,182    

268,929

 
           
TOTAL  $163,634   $434,569 

 

Income taxes

 

The Company adopted the ASC Topic 740, “Income Taxes” paragraph 740-10-25-13, which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the unaudited condensed consolidated financial statements. Under paragraph 740-10-25-13, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Paragraph 740-10-25-13 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no material adjustments to its liabilities for unrecognized income tax benefits according to the provisions of paragraph 740-10-25-13.

 

9

 

 

The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying balance sheets, as well as tax credit carry-backs and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its balance sheets and provides valuation allowances as management deems necessary.

 

Uncertain tax positions

 

The Company did not take any uncertain tax positions and had no adjustments to its income tax liabilities or benefits pursuant to the ASC Topic 740 provisions of Section 740-10-25 for the three and six months ended June 30, 2022 and 2021, respectively.

 

Foreign currencies translation

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the condensed consolidated statement of operations.

 

The reporting currency of the Company is United States Dollar (“US$”) and the accompanying financial statements have been expressed in US$. In addition, the Company is operating in Hong Kong SAR and the People’s Republic of China and maintain its books and record in its local currency, Hong Kong Dollars (“HK$”) and Renminbi (“RMB”), which is a functional currency as being the primary currency of the economic environment in which their operations are conducted. In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the year. The gains and losses resulting from translation of financial statements of foreign subsidiaries are recorded as a separate component of accumulated other comprehensive income within the statements of changes in shareholders’ equity.

 

Translation of amounts from HK$ and RMB into US$ has been made at the following exchange rates for the six months ended June 30, 2022 and 2021:

 

   2022   2021 
Period-end HK$:US$ exchange rate   0.12744    0.12878 
Period average HK$:US$ exchange rate   0.12779    0.12884 
Period-end RMB:US$ exchange rate   0.14930    0.15484 
Period average RMB:US$ exchange rate   0.15438    0.15461 

 

Net loss per share

 

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic income per share is computed by dividing the net income by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed similar to basic income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

 

Comprehensive income

 

ASC Topic 220, “Comprehensive Income”, establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying condensed consolidated statements of changes in stockholders’ equity, consists of changes in unrealized gains and losses on foreign currency translation. This comprehensive income is not included in the computation of income tax expense or benefit.

 

Leases

 

The Company adopted ASC Topic 842, “Leases”, using the modified retrospective approach through a cumulative-effect adjustment and utilizing the effective date of January 1, 2019 as its date of initial application, with prior periods unchanged and presented in accordance with the previous guidance in ASC Topic 840, “Leases”.

 

10

 

 

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases with a term greater than one year are recognized on the balance sheet as right-of-use (“ROU”) assets, lease liabilities and long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued lease payments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

 

In accordance with the guidance in ASC Topic 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Subsequently, the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.

 

Lease expense is recognized on a straight-line basis over the lease terms. Lease expense includes amortization of the ROU assets and accretion of the lease liabilities. Amortization of ROU assets is calculated as the periodic lease cost less accretion of the lease liability. The amortized period for ROU assets is limited to the expected lease term.

 

The Company has elected a practical expedient to combine the lease and non-lease components into a single lease component. The Company also elected the short-term lease measurement and recognition exemption and does not establish ROU assets or lease liabilities for operating leases with terms of 12 months or less.

 

Related parties

 

The Company follows the ASC Topic 850-10, “Related Party Disclosures” for the identification of related parties and disclosure of related party transactions.

 

Pursuant to section 850-10-20 the related parties include a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and Income-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amount due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 

Commitments and contingencies

 

The Company follows the ASC Topic 450-20, “Contingencies” to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

 

11

 

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

 

Fair value of financial instruments

 

The Company follows ASC Topic 825 “Financial Instruments” paragraph 825-10-50-10 for disclosures about fair value of its financial instruments and has adopted paragraph 820-10-35-37 to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by paragraph 820-10-35-37 are described below:

 

  Level 1   Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
  Level 2   Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
  Level 3   Pricing inputs that are generally observable inputs and not corroborated by market data.

 

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.

 

The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash and cash equivalents, approximate their fair values because of the short maturity of these instruments.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about geographical areas, business segments and major customers in consolidated financial statements. Currently, the Company operates in one reportable operating segment in Hong Kong and China.

 

Recent accounting pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), (“ASU 2021-04”). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 on January 1, 2022 did not have a material impact on the Company’s financial statements or disclosures.

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

 

12

 

 

NOTE 3 - SEGMENT REPORTING 

 

Currently, the Company has two reportable business segments:

 

(i) Healthcare Segment, mainly provides health consulting advisory services and healthcare and wellness products to the customers; and
(ii) Wine Segment, mainly provides the wine products to the customers.

 

                
   Three months ended 30 June, 2022 
   Healthcare Segment  

Wine

Segment

   Total 
Revenue from external customers:               
Consulting service income  $71,394   $   $71,394 
Sale of healthcare products       23,441    23,441 
Total revenue   71,394    23,441    94,835 
                
Cost of sales:               
Consulting service income   (14,025)   -    (14,025)
Sale of healthcare products   -    (14,449)   (14,449)
Total cost of revenue   (14,025)   (14,449)   (28,474)
                
Gross profit   57,369    8,992    66,361 
                
Operating Expenses               
Selling and distribution   -    (2,642)   (2,642)
General and administrative   (33,055)   (74,707)   (107,762)
Total operating expenses   (33,055)   (77,349)   (110,404)
                
Segment income (loss)  $24,314   $(68,357)  $(44,043)

 

                
   Three months ended 30 June, 2021 
   Healthcare Segment  

Wine

Segment

   Total 
Revenue from external customers:               
Consulting service income  $165,640   $   $165,640 
Sale of healthcare products       101,286    101,286 
Total revenue   165,640    101,286    266,926 
                
Cost of sales:               
Consulting service income   (10,803)   -    (10,803)
Sale of healthcare products   -    (48,481)   (48,481)
Total cost of revenue   (10,803)   (48,481)   (59,284)
                
Gross profit   154,837    52,805    207,642 
                
Operating Expenses               
Selling and distribution   -    (2,563)   (2,563)
General and administrative   (32,381)   (138,419)   (170,800)
Total operating expenses   (32,381)   (140,982)   (173,363)
                
Segment income (loss)  $122,456   $(88,177)  $34,279

 

                
   Six months ended June 30, 2022 
   Healthcare Segment   Wine Segment   Total 
Revenue from external customers:               
Consulting service income  $135,452   $   $135,452 
Sale of healthcare products       28,182    28,182 
Total revenue   135,452    28,182    163,634 
                
Cost of sales:               
Consulting service income   (28,268)   -    (28,268)
Sale of healthcare products   -    (19,043)   (19,043)
Total cost of revenue   (28,268)   (19,043)   (47,311)
                
Gross profit   107,184    9,139    116,323 
                
Operating Expenses               
Selling and distribution   -    (2,650)   (2,650)
General and administrative   (64,534)   (168,157)   (232,691)
Total operating expenses   (64,534)   (170,807)   (235,341)
                
Segment income (loss)  $42,650   $(161,668)  $(119,018)

 

13

 

 

                
   Six months ended June 30, 2021 
   Healthcare Segment   Wine Segment   Total 
Revenue from external customers:               
Consulting service income  $165,640   $   $165,640 
Sale of healthcare products       268,929    268,929 
Total revenue   165,640    268,929    434,569 
                
Cost of sales:               
Consulting service income   (10,803)   -    (10,803)
Sale of healthcare products   -    (202,165)   (202,165)
Total cost of revenue   (10,803)   (202,165)   (212,968)
                
Gross profit   154,837    66,764    221,601 
                
Operating Expenses               
Selling and distribution   -    (14,212)   (14,212)
General and administrative   (67,220)   (317,756)   (384,976)
Total operating expenses   (67,220)   (331,968)   (399,188)
                
Segment income (loss)  $87,617   $(265,204)  $(177,587)

 

NOTE 4 - PREPAYMENTS AND OTHER RECEIVABLES

 

Prepayments and other receivables consisted of the following:

 

           
   June 30, 2022   December 31, 2021 
         
Prepayments  $-   $3,077 
Other deposits   33,777    33,961 
Other receivables   90,179    102,216 
Prepayments and other receivable  $123,956   $139,254 

 

Other receivables represented deposit payments made to suppliers for daily operation, procurement, which are interest-free, unsecured and received by the Company when cooperation with suppliers are terminated.

 

NOTE 5 - INVENTORIES

 

Inventories consisted of the following:

 

           
   June 30, 2022   December 31, 2021 
         
Finished goods  $300,521   $327,551 

 

For the three and six months ended June 30, 2022 and 2021, no allowance for obsolete inventories was recorded by the Company.

 

14

 

 

NOTE 6 - LEASE

 

The Company leased office and warehouse facilities under various non-cancelable operating leases expiring at the term of 2 to 4 years, through December 31, 2025.

 

Right of use assets and lease liability – right of use are as follows:

 

           
   June 30, 2022   December 31, 2021 
           
Right-of-use assets  $278,235   $350,563 

 

The lease liability – right of use is as follows:

 

           
   June 30, 2022   December 31, 2021 
         
Current portion   106,888    114,132 
Non-current portion   183,050    246,022 
           
Total  $289,938   $360,154 

 

As of June 30, 2022, the operating lease payment of $106,888 will become matured in the next 12 months.

 

NOTE 7 - PLANT AND EQUIPMENT

 

           
   June 30, 2022   December 31, 2021 
         
Motor vehicle  $311,343   $311,343 
Furniture, fixture and equipment   15,465    15,465 
Leasehold improvement   27,358    27,358 
Foreign translation adjustment   2,841    17,603 
Plant and equipment, gross   357,007    371,769 
           
Less: accumulated depreciation   (264,698)   (228,507)
Foreign translation adjustment   557    (10,658)
Plant and equipment, net  $92,866   $132,604 

 

Depreciation expense for the three and six months ended June 30, 2022 were $16,573 and $36,191, respectively.

 

Depreciation expense for the three and six months ended June 30, 2021 were $21,241 and $42,671, respectively.

 

NOTE - 8 AMOUNTS DUE TO A DIRECTOR AND A RELATED COMPANY

 

As of June 30, 2022 and December 31, 2021, the amounts represented temporary advances to the Company by its director and its related company which were unsecured, interest-free and have no fixed terms of repayments.

 

NOTE 9 – SHAREHOLDERS’ EQUITY

 

Preferred Stock

 

The Company is not currently authorized to issue shares of preferred stock. The Certificate of Incorporation however, allows the board of directors to authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock in the event that shares of preferred stock are authorized in the future. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and may adversely affect the market price of our common stock and the voting and other rights of the holders of common stock. The Company has no current plans to issue any shares of preferred stock.

 

Common Stock

 

The Company is authorized, subject to limitations prescribed by Delaware law, to issue up to 100,000,000 shares of common stock with a nominal par value of $0.0001.

 

15

 

 

Dividend Rights

 

Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and only then at the times and in the amounts that our board of directors may determine.

 

Voting Rights

 

Each holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Under our Certificate of Incorporation, stockholders do not have the right to cumulate votes for the election of directors.

 

No Preemptive or Similar Rights

 

Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions.

 

Right to Receive Liquidation Distributions

 

Upon our dissolution, liquidation or winding-up, the assets legally available for distribution to our stockholders are distributable ratably among the holders of our common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of preferred stock.

 

As of June 30, 2022, and December 31, 2021, a total of 20,252,309 and 20,252,309 outstanding shares of common stock were issued, respectively.

 

NOTE 10 - INCOME TAXES

 

The provision for income taxes consisted of the following:

 

           
   Six months ended June 30, 
   2022   2021 
         
Current tax  $6,573   $- 
Deferred tax   -    - 
Income tax expense  $6,573   $- 

 

The Company mainly operates in the PRC that is subject to taxes in the governing jurisdictions in which it operates. The effective tax rate in the years presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rate, as follows:

 

BVI

 

Under the current BVI law, the Company is not subject to tax on income.

 

16

 

 

The PRC

 

The Company’s subsidiary operating in the PRC is subject to the Corporate Income Tax Law of the People’s Republic of China at a unified income tax rate of 25%. The reconciliation of income tax rate to the effective income tax rate for the six months ended June 30, 2022 and 2021 is as follows:

 

           
   Six months ended June 30, 
   2022   2021 
         
Loss before income taxes  $(152,669)  $(257,606)
Statutory income tax rate   25%   25%
Income tax expense at statutory rate   (38,167)   (64,402)
Net operating loss   38,167    64,402 
Income tax expense  $-   $- 

 

Hong Kong

 

The Company’s subsidiary operating in Hong Kong is subject to the Hong Kong Profits Tax at the two-tiered profits tax rates from 8.25% to 16.5% on the estimated assessable profits arising in Hong Kong during the current year, after deducting a tax concession for the tax year. The reconciliation of income tax rate to the effective income tax rate for the six months ended June 30, 2022 and 2021 is as follows:

 

           
   Six months ended June 30, 
   2022   2021 
         
Profit before income taxes  $55,876   $103,283 
Statutory income tax rate   8.25%   8.25%
Income tax expense at statutory rate   4,610    8,521 
Tax adjustments   1,963    - 
One-off tax reduction   -    (8,521)
Income tax expense  $6,573   $- 

 

The following table sets forth the significant components of the deferred tax assets of the Company as of June 30, 2022 and December 31, 2021:

 

           
   June 30, 2022   December 31, 2021 
         
Deferred tax assets:          
Net operating loss carryforwards          
- United States  $43,086    54,747 
- PRC   315,729    246,903 
Net operating loss carryforwards   358,815    301,650 
Less: valuation allowance   (358,815)   (301,650)
Deferred tax assets, net  $-   $- 

 

NOTE 11 - RELATED PARTY TRANSACTIONS

 

From time to time, the Company’s director advanced funds to the Company for working capital purpose. Those advances are unsecured, non-interest bearing and due on demand.

 

The Company has been provided free office space by its stockholder. The management determined that such cost is nominal and did not recognize the rent expense in its condensed consolidated financial statements.

 

Apart from the transactions and balances detailed elsewhere in these accompanying unaudited condensed consolidated financial statements, the Company has no other significant or material related party transactions during the periods presented.

 

17

 

 

NOTE 12 - CONCENTRATIONS OF RISK

 

The Company is exposed to the following concentrations of risk:

 

(a) Major customers

 

For the three and six months ended June 30, 2022 and 2021, the customers who account for 10% or more of the Company’s revenues and its outstanding receivables balance as at period-end dates, are presented as follows:

 

           
   Three Months ended June 30, 2022 
Customer  Revenues  

Percentage of

revenues

 
         
Customer C  $71,394    75%
Customer D   14,084    15%
           
Total:  $85,478    90%

 

   Six months ended June 30, 2022       June 30, 2022 
Customer  Revenues  

Percentage of

revenues

      

Accounts

receivable

  

Percentage of

Accounts

Receivable

 
                     
Customer C   135,452    83%        -    - 
                          
Total:  $135,452    83%   Total    -    - 

 

   Three Months ended June 30, 2021 
Customer  Revenues  

Percentage of

revenues

 
         
Customer A  $84,877    32%
Customer B   165,640    62%
           
Total:  $250,517    94%

 

   Six Months ended June 30, 2021   June 30,2021 
Customer  Revenues  

Percentage of

revenues

  

Accounts

receivable

  

Percentage of

Accounts

Receivable

 
                 
Customer A  $252,520    58%   164,682    98%
Customer B   165,640    40%   -    - 
                     
Total:  $418,160    98%   164,682   98%

 

The Company’s customers are located in the People’s Republic of China and Hong Kong.

 

(a) Major vendors

 

For the three and six months ended June 30, 2022, a single vendor represented more than 10% of the Company’s purchases. This vendor accounted for 100% of the Company’s purchases amounting to $0 with $0 of accounts payable and amounting to $7,981 with $0 of accounts payable, respectively.

 

For the three and six months ended June 30, 2021, a single vendor represented more than 10% of the Company’s purchases. This vendor accounted for 100% of the Company’s purchases amounting to $69,444 with $0 of accounts payable and amounting to $193,186 with $0 of accounts payable, respectively.

 

18

 

 

All of the Company’s vendors are located in the People’s Republic of China.

 

(c) Credit risk

 

Financial instruments that are potentially subject to credit risk consist principally of trade receivables. The Company believes the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

 

(d) Economic and political risk

 

The Company’s major operations are conducted in the People’s Republic of China. Accordingly, the political, economic, and legal environments in PRC, as well as the general state of PRC’s economy may influence the Company’s business, financial condition, and results of operations.

 

(e) Exchange rate risk

 

The Company cannot guarantee that the current exchange rate will remain steady; therefore there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RMB converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

 

NOTE 13 - COMMITMENTS AND CONTINGENCIES

 

As of June 30, 2022, the Company has no material commitments or contingencies.

 

NOTE 14 - SUBSEQUENT EVENTS

 

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred after June 30, 2022 up through the date the Company issued the unaudited condensed consolidated financial statements. During the period, the Company did not have any material recognizable subsequent events.

 

19

 

 

Item 2. Management’s Discussion and Analysis or Plan of Operation.

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This periodic report contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations, business strategies, operating efficiencies or synergies, competitive positions, growth opportunities for existing products, plans and objectives of management. Statements in this periodic report that are not historical facts are hereby identified as forward-looking statements. Our Company and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this Quarterly Report and other filings with the Securities and Exchange Commission and in reports to our Company’s stockholders. Management believes that all statements that express expectations and projections with respect to future matters, as well as from developments beyond our Company’s control including changes in global economic conditions are forward-looking statements within the meaning of the Act. These statements are made on the basis of management’s views and assumptions, as of the time the statements are made, regarding future events and business performance. There can be no assurance, however, that management’s expectations will necessarily come to pass. Factors that may affect forward-looking statements include a wide range of factors that could materially affect future developments and performance, including the following:

 

Changes in Company-wide strategies, which may result in changes in the types or mix of businesses in which our Company is involved or chooses to invest; changes in U.S., global or regional economic conditions; changes in U.S. and global financial and equity markets, including significant interest rate fluctuations, which may impede our Company’s access to, or increase the cost of, external financing for our operations and investments; increased competitive pressures, both domestically and internationally; legal and regulatory developments, such as regulatory actions affecting environmental activities; the imposition by foreign countries of trade restrictions and changes in international tax laws or currency controls; adverse weather conditions or natural disasters, such as hurricanes and earthquakes; and labor disputes, which may lead to increased costs or disruption of operations.

 

This list of factors that may affect future performance and the accuracy of forward-looking statements are illustrative, but by no means exhaustive. Accordingly, all forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

 

Business Overview

 

We are a health and wellness company that develops, markets, promotes and distributes a variety of customized health and wellness care products and services, including supplements, healthy snacks, meal replacements, skincare products, and nutritional consultation services to consumers in China. We work with certain licensed healthcare food factories to develop and manufacture products and services that are distributed conventionally through sales agents and also through a network of e-commerce and social media platforms.

 

In addition to products, we are committed to providing customized science based wellness consultation and service programs to customers. Our diverse products and services target health conscious customers and differentiate based upon age and gender and seek to manage different conditions. We reach out to customers fitting certain health and lifestyle profiles through our offline and online consultation services, and track eating habits and health indicators to provide customized products such as supplements. We believe this will facilitate the ability of customers to monitor, understand and adjust their health practices and lifestyle anytime and anywhere for increased customer engagement and retention.

 

We conduct our business through our wholly owned subsidiary Guangzhou Xiao Xiang Health Industry Company Limited, a limited liability company organized under the laws of China on March 8, 2017 and Alpha Wellness (HK) Limited, a limited liability company organized under the laws of Hong Kong on April 24, 2019. Elite Creation Group, a limited liability company formed under the laws of the British Virgin Islands formed on September 5, 2018, is holding companies without operations.

 

20

 

 

Discussion and Analysis of Financial Condition and Results of Operations

 

RESULTS OF OPERATIONS

 

We have been significantly impacted by COVID-19 global pandemic. In addition to the devastating effects on human life, the pandemic is having a negative ripple effect on the global economy, leading to disruptions and volatility in the global financial markets. China and many other countries have issued policies intended to stop or slow the further spread of the disease.

 

COVID-19 and China’s response to the pandemic are significantly affecting the economy. There are no comparable events that provide guidance as to the effect the COVID-19 pandemic may have, and, as a result, the ultimate effect of the pandemic is highly uncertain and subject to change. We do not yet know the full extent of the effects on the economy, the markets we serve, our business or our operations.

 

The following table sets forth certain operational data for the three and six months ended June 30, 2022 and 2021:

 

   Three Months Ended   Three Months Ended 
   June 30, 2022   June 30, 2021 
Revenue, net  $94,835   $266,926 
Cost of revenue   (28,474)   (59,284)
Gross profit   66,361    207,642 
Total operating expenses   (110,404)   (173,363)
Total other income   10,625    391 
(Loss) income before income tax   (33,418)   34,670 
Income tax expenses   (4,305)   - 
Net (loss) income   (37,723)   34,670 

 

   Six Months Ended   Six Months Ended 
   June 30, 2022   June 30, 2021 
Revenue, net  $163,634   $434,569 
Cost of revenue   (47,311)   (212,968)
Gross profit   116,323    221,601 
Total operating expenses   (235,341)   (399,188)
Total other income   11,044    7,190 
Loss before income tax   (107,974)   (170,397)
Income tax expenses   (6,573)   - 
Net loss   (114,547)   (170,397)

 

Revenue. For the three and six months ended June 30, 2022, we generated revenues of $94,835 and $163,634, respectively. For the comparative three and six months ended June 30, 2021, we generated revenues of $266,926 and $434,569, respectively. The significant decrease in revenue because a significant drop in the sales of $240,747 in the PRC. The major customers are located in Hong Kong during the period ended June 30, 2022, while the major customers are located in the PRC during the period ended June 30, 2021.

 

Cost of Revenue. For the three and six months ended June 30, 2022, the cost of revenue was $28,474 and $47,311, respectively, and as a percentage of net revenue, approximately 30% and 29%. Cost of revenue for the three and six months ended June 30, 2021 was $59,284 and $212,968, respectively, and as a percentage of net revenue, approximately 22% and 49%, respectively. The cost of revenue decreased due to a significant drop in the sales in the PRC and the major income was from Hong Kong mentioned above.

 

21

 

 

Operation expenses. For the three and six months ended June 30, 2022, the operation cost was $110,404 and $235,341, respectively, and while for the three and six months ended June 30, 2021 was $173,363 and $399,188, respectively. The operation expenses decreased due to a decrease in administrative expenses.

 

Other income. For the three and six months ended June 30, 2022, the other income was $10,625 and $11,044, respectively and while for the three and six months ended June 30, 2021 was $391 and $7,190, respectively. The other income increased due to receipt of government subsidies during the period ended June 30, 2022.

 

Net Loss. For the three and six months ended June 30, 2022, we incurred a net loss of $37,723 and $114,547, respectively and while for the three and six months ended June 30, 2021, we incurred a net income of $34,670 and net loss of $170,397, respectively. The decrease in net loss is primarily attributable to the decrease in administrative expenses and decrease in revenue.

 

Liquidity and Capital Resources

 

As of June 30, 2022, we had cash and cash equivalents of $477,214, inventories of $300,521, right-of-use assets of $278,235, tax recoverable of $70, and prepayments and other receivables of $123,956.

 

As of December 31, 2021, we had cash and cash equivalents of $609,434, inventories of $327,551, right-of-use assets of $350,563, tax recoverable of $8,910, and prepayments and other receivables of $139,254.

 

We believe that our current cash and other sources of liquidity discussed below are adequate to support general operations for at least the next 12 months.

 

   Six Months Ended June 30, 
   2022   2021 
Net cash used in operating activities  $(126,912)  $(277,780)
Net cash used in investing activities   -    - 
Net cash (used in) provided by financing activities   (4,796)   50,178 

 

Net Cash Used In Operating Activities.

 

For the six months ended June 30, 2022, net cash used in operating activities was $126,912, which consisted primarily of decrease in prepayments and other receivables of $15,298, decrease in inventories of $27,030, increase in accrued liabilities and other payables of $7,139, increase in income tax payable of 8,840, decrease in customers deposits of $93,832, and decrease in lease liabilities of $49,104.

 

For the six months ended June 30, 2021, net cash used in operating activities was $277,780, which consisted primarily of the increase in accounts receivables of $167,223, increase in prepayments and other receivables of $9,185, decrease in inventories of $65,411, increase in accrued liabilities and other payables of $46,084, decrease in accounts payable of $7,827, increase in income tax payable of 7,305, decrease in customers deposits of $128,499, and increase in lease liabilities of $36,135.

 

We expect to continue to rely on cash generated through financing from our existing shareholders and private placements of our securities, however, to finance our operations and future acquisitions.

 

Net Cash Used In Investing Activities.

 

For the six months ended June 30, 2022, there is no net cash used in investing activities.

 

For the six months ended June 30, 2021, there is no net cash used in investing activities.

 

Net Cash (Used In) Provided By Financing Activities.

 

For the six months ended June 30, 2022, net cash used in financing activities was $4,796, which consisted primarily of repayment to a director of $4,796

 

For the six months ended June 30, 2021, net cash provided by financing activities was $50,178, which consisted primarily of advance from a director of $81,899 and repayment of lease liabilities of $31,721.

 

22

 

 

Off Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements and it is not anticipated that the Company will enter into any off-balance sheet arrangements.

 

Critical Accounting Policies, Judgments and Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires our management to make assumptions, estimates and judgments that affect the amounts reported, including the notes thereto, and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant to the preparation of our financial statements. These accounting policies are important for an understanding of our financial condition and results of operations. Critical accounting policies are those that are most important to the presentation of our financial condition and results of operations and require management’s subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting the estimate may differ significantly from management’s current judgments. We believe the following accounting policies are critical in the preparation of our financial statements.

 

The Company’s accounting policies are more fully described in Note 2 of the financial statements. As discussed in Note 2, the preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about the future events that affect the amounts reported in the financial statements and the accompanying notes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual differences could differ from these estimates under different assumptions or conditions. The Company believes that the following addresses the Company’s most critical accounting policies.

 

Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets will be reflected on the balance sheet when it is determined that it is more likely than not that the asset will be realized. A valuation allowance has currently been recorded to reduce our deferred tax asset to $0.

 

Forward-looking Statements

 

The Private Securities Litigation Reform Act of 1995 (the “Act”) provides a safe harbor for forward-looking statements made by or on behalf of our Company. Our Company and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this report and other filings with the Securities and Exchange Commission and in reports to our Company’s stockholders. Management believes that all statements that express expectations and projections with respect to future matters, as well as from developments beyond our Company’s control including changes in global economic conditions are forward-looking statements within the meaning of the Act. These statements are made on the basis of management’s views and assumptions, as of the time the statements are made, regarding future events and business performance. There can be no assurance, however, that management’s expectations will necessarily come to pass. Factors that may affect forward-looking statements include a wide range of factors that could materially affect future developments and performance, including the following:

 

Changes in Company-wide strategies, which may result in changes in the types or mix of businesses in which our Company is involved or chooses to invest; changes in U.S., global or regional economic conditions; changes in U.S. and global financial and equity markets, including significant interest rate fluctuations, which may impede our Company’s access to, or increase the cost of, external financing for our operations and investments; increased competitive pressures, both domestically and internationally; legal and regulatory developments, such as regulatory actions affecting environmental activities; the imposition by foreign countries of trade restrictions and changes in international tax laws or currency controls; adverse weather conditions or natural disasters, such as hurricanes and earthquakes; and labor disputes, which may lead to increased costs or disruption of operations.

 

This list of factors that may affect future performance and the accuracy of forward-looking statements is illustrative, but by no means exhaustive. Accordingly, all forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

 

23

 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures

 

Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining disclosure controls and procedures for the Company.

 

(a) Evaluation of Disclosure Controls and Procedures

 

Our management evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, our President and Principal Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were not effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected but we believe the controls and procedures do provide a reasonable assurance.

 

(b) Changes in the Company’s Internal Controls Over Financial Reporting

 

There have been no changes in internal control over financial reporting that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the internal control over financial reporting.

 

Part II - Other Information

 

Item 1. Legal Proceedings

 

There are no legal proceedings, which are pending or have been threatened against us or any of our officers, directors or control persons of which management is aware.

 

Item 1A. Risk Factors

 

Not applicable to smaller reporting companies.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Recent Sales of Unregistered Securities

 

We have not sold any restricted securities during the three and six months ended June 30, 2022.